报价延迟最少15分钟:2025/07/20 13:07 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
18.68 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-6.20/-7.33
|
|
企业价值
150.03M
|
| 资产负债 |
|
每股账面净值
3.55
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
28.52M
|
|
每股收益
11.82
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟：2025/07/20 13:07 EDT
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program. |
